Moderna Tops BioSpace’s 2022 Best Places to Work Ranking in Large Employer Category
November 17 2021 - 8:45AM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines, today announced it
was ranked the number one employer in BioSpace’s 2022 Best Places
to Work in Biopharma report.
“We are honored to be recognized by BioSpace for career growth
and development, leadership, culture, benefits, and innovation and
drug pipeline. This is another recognition our employees’
dedication and relentless pursuit of our mission,” said Stéphane
Bancel, Chief Executive Officer of Moderna. “Since our founding, we
have been committed to bringing a new class of mRNA medicines to
people around the world. Being recognized as a great place to work
is meaningful when looking at where we began as a company, and as
we grow, we are focused on maintaining the values and mindsets we
have had since the beginning.”
Over the past year, Moderna’s COVID-19 response efforts created
hundreds of jobs, increasing its employee numbers from 800 in 2019
to more than 2,400 employees as of September 2021. The Company is
making several investments to support employees as the organization
continues to scale, and recently announced an expansion of the
Moderna Technology Center in Norwood, including more than doubling
of space to transform the facility from a production and lab space
to an industrial technology center.
Additionally, the Company will invest in a new Moderna Science
Center, a purpose-built space to support the Company’s next chapter
of discovery. Beyond expanding the physical space where employees
can innovate, the Company remains committed to upholding its
founding values, maintaining an inclusive culture and investing in
training and development programs to support employees through
another exciting year for Moderna.
Conducted in September 2021, research for the BioSpace ranking
included responses from over 2,000 life sciences professionals.
Respondents were asked to identify their top three most desirable
biopharma companies, segmented by large (defined as more than 1,000
employees) and small (fewer than 1,000 employees) companies.
Respondents were also asked to rate the importance of 10 attributes
(i.e., benefits, etc.) when thinking of top employers. Career
growth and development were rated most highly, followed by
leadership and pay. To view the complete lists of 2022 Best Places
to Work, click here.
About Moderna
In 10 years since its inception, Moderna has transformed from a
science research-stage company advancing programs in the field of
messenger RNA (mRNA), to an enterprise with a diverse clinical
portfolio of vaccines and therapeutics across six modalities, a
broad intellectual property portfolio in areas including mRNA and
lipid nanoparticle formulation, and an integrated manufacturing
plant that allows for both clinical and commercial production at
scale and at unprecedented speed. Moderna maintains alliances with
a broad range of domestic and overseas government and commercial
collaborators, which has allowed for the pursuit of both
groundbreaking science and rapid scaling of manufacturing. Most
recently, Moderna’s capabilities have come together to allow the
authorized use of one of the earliest and most effective vaccines
against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advances in basic
and applied mRNA science, delivery technology and manufacturing,
and has allowed the development of therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular
diseases and auto-immune diseases. Moderna has been named a top
biopharmaceutical employer by Science for the past seven years. To
learn more, visit www.modernatx.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including regarding: the Company’s investments in
its workforce, and investments in the expansion of the Moderna
Technology center and its Moderna Science Center. The
forward-looking statements in this press release are neither
promises nor guarantees, and you should not place undue reliance on
these forward-looking statements because they involve known and
unknown risks, uncertainties, and other factors, many of which are
beyond Moderna’s control and which could cause actual results to
differ materially from those expressed or implied by these
forward-looking statements. These risks, uncertainties, and other
factors include those other risks and uncertainties described under
the heading “Risk Factors” in Moderna’s most recent Annual Report
on Form 10-K filed with the U.S. Securities and Exchange Commission
(SEC) and in subsequent filings made by Moderna with the SEC, which
are available on the SEC’s website at www.sec.gov. Except as
required by law, Moderna disclaims any intention or responsibility
for updating or revising any forward-looking statements contained
in this press release in the event of new information, future
developments or otherwise. These forward-looking statements are
based on Moderna’s current expectations and speak only as of the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211117005889/en/
Moderna Contacts
Media: Colleen Hussey Director, Corporate Communications
617-335-1374 Colleen.Hussey@modernatx.com
Investors: Lavina Talukdar Senior Vice President &
Head of Investor Relations 617-209-5834
Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024